Key Points
- Director Ping Ji sold 5,000 Adlai Nortye shares at an average price of $16.63, generating $83,150. Following the transaction, Ji retained 131,667 shares, a 3.66% reduction in ownership.
- Adlai Nortye shares opened at $15.83, near their 52-week high of $17.25, with the stock trading above its 50-day and 200-day moving averages.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $29.50; institutional investors own 35.21% of the company.
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) Director Ping Ji sold 5,000 shares of the company's stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $16.63, for a total transaction of $83,150.00. Following the sale, the director directly owned 131,667 shares in the company, valued at $2,189,622.21. This represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Adlai Nortye Stock Performance
NASDAQ ANL opened at $15.83 on Friday. Adlai Nortye Ltd. Sponsored ADR has a 1-year low of $0.88 and a 1-year high of $17.25. The company has a 50 day moving average of $13.98 and a 200-day moving average of $12.00. The company has a quick ratio of 0.65, a current ratio of 9.55 and a debt-to-equity ratio of 0.04.
Analysts Set New Price Targets
A number of research firms recently weighed in on ANL. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Adlai Nortye in a report on Tuesday, September 8th. Jefferies Financial Group initiated coverage on Adlai Nortye in a report on Thursday, September 10th. They set a "buy" rating and a $31.00 target price on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Adlai Nortye in a research note on Tuesday, July 14th. Loop Capital set a $49.00 price target on Adlai Nortye in a report on Tuesday, September 8th. Finally, Wall Street Zen downgraded shares of Adlai Nortye from a "buy" rating to a "hold" rating in a research report on Saturday, September 12th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $29.50.
Get Our Latest Analysis on Adlai Nortye
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of ANL. Braidwell LP acquired a new stake in shares of Adlai Nortye in the 2nd quarter valued at $9,145,000. Boone Capital Management LLC acquired a new position in shares of Adlai Nortye during the second quarter valued at $2,971,000. ADAR1 Capital Management LLC acquired a new position in shares of Adlai Nortye during the first quarter valued at $816,000. Seven Fleet Capital Management LP bought a new position in Adlai Nortye in the second quarter valued at about $1,302,000. Finally, Affinity Asset Advisors LLC bought a new position in Adlai Nortye in the first quarter valued at about $1,140,000. 35.21% of the stock is currently owned by institutional investors.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company's research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.
Adlai Nortye's lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
